The PSMA4 (Proteasome Subunit Alpha 4) gene encodes a critical component of the 20S proteasome core particle, the central enzymatic complex responsible for ubiquitin-dependent protein degradation in eukaryotic cells. Located at chromosomal position 15q21.3, PSMA4 is one of seven alpha subunits that form the outer rings of the proteasome barrel structure. This gene is essential for maintaining cellular protein homeostasis, and its dysfunction has been implicated in various neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS).
| Gene Symbol | PSMA4 |
| Full Name | Proteasome Subunit Alpha 4 |
| Chromosomal Location | 15q21.3 |
| NCBI Gene ID | 5685 |
| OMIM | 176844 |
| Ensembl ID | ENSG00000123131 |
| UniProt | P25789 |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Amyotrophic Lateral Sclerosis |
PSMA4 encodes the alpha subunit type 4 of the 20S proteasome, a highly conserved cylindrical particle consisting of four stacked heptameric rings. The two outer rings contain alpha subunits (PSMA1-7) that regulate substrate entry into the proteolytic chamber, while the two inner rings contain beta subunits (PSMB1-7) that carry the catalytic activities[1]. PSMA4 specifically contributes to the structural integrity of the alpha ring and participates in the recognition and unfolding of ubiquitinated protein substrates.
In neurons, the proteasome plays a crucial role in degrading misfolded proteins, regulatory transcription factors, and aggregation-prone proteins that accumulate during aging and stress. The ubiquitin-proteasome system (UPS) is particularly important in synaptic plasticity, where rapid protein turnover is required for learning and memory processes[2].
PSMA4 is a 26 kDa protein that assembles with six other alpha subunits (PSMA1-3, PSMA5-7) to form the heptameric alpha ring. This ring serves as the gatekeeper for the proteolytic chamber, controlling access of substrates to the catalytic beta subunits. The alpha subunits contain N-terminal tails that can be modified by phosphorylation or acetylation, which regulate proteasome activity and substrate recognition[3].
The 20S proteasome degrades proteins tagged with polyubiquitin chains, first removing the ubiquitin molecules and then unfolding the substrate for proteolytic cleavage. PSMA4 contributes to this process by:
In the central nervous system, PSMA4 and the proteasome are essential for:
Proteasome dysfunction is a well-documented feature of Alzheimer's disease brain. Studies have shown reduced 20S proteasome activity in AD hippocampus and cortex, with altered expression of alpha subunit proteins including PSMA4. This impairment contributes to the accumulation of ubiquitinated protein aggregates in AD brain. Furthermore, amyloid-beta peptides can directly inhibit proteasome activity, creating a vicious cycle of protein homeostasis failure[5].
The pathogenesis of Parkinson's disease involves progressive loss of dopaminergic neurons in the substantia nigra, a process linked to proteasome dysfunction. alpha-Synuclein, the key protein in Lewy body formation, is normally degraded by the UPS. When proteasome function is compromised, alpha-synuclein accumulates and forms toxic oligomers. PSMA4 expression changes have been observed in PD brain tissue[6].
ALS involves progressive motor neuron degeneration, and UPS impairment has been implicated in disease pathogenesis. Mutations in genes encoding proteasome subunits and ubiquitin ligases cause familial ALS. Additionally, aggregated TDP-43 proteins, a hallmark of ALS pathology, are substrates of the proteasome[7].
Age-related cognitive decline is associated with reduced proteasome activity in brain. The decline in proteasome function may contribute to the accumulation of damaged proteins and the cognitive deficits seen in normal aging. Exercise and caloric restriction have been shown to upregulate proteasome activity and improve cognitive function[8].
PSMA4 is ubiquitously expressed in all tissues, with high expression in metabolically active cells:
The proteasome is a validated drug target in oncology (bortezomib), and similar approaches are being explored for neurodegenerative diseases. PSMA4 modulators could potentially:
The study of Psma4 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Groll et al. [Structure of the 20S Proteasome (2000)](https://doi.org/10.1016/S0092-8674(00). 2000. ↩︎
Hegde et al. Proteasome Regulation of Synaptic Plasticity (2020). 2020. ↩︎
Tsakiri et al. Proteasome and Neuronal Survival (2014). 2014. ↩︎
Gregori et al. Proteasome Dysfunction in AD (1995). 1995. ↩︎
McNaught et al. Proteasome Impairment in PD (2001). 2001. ↩︎
Keller et al. Proteasome and Aging Brain (2000). 2000. ↩︎